Latest Breaking News On - Olivier danos - Page 1 : comparemela.com

Phase 1/2 Findings Highlight RGX-202 s Safety, Impact on Key Duchenne Biomarkers

RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.

United statesAravindhan veerapandiyanOlivier danosManufacturing innovation centerWorld muscle societyInternational congressArkansas childrenNorth star ambulatory assessmentInnovation centerRgx 202Duchenne muscular dystrophyLevel 1 dosageSerum creatine kinaseAffinity duchenne

Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform

Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBruxelles capitaleRegion flamandeFrance generalRobert kotinMark kayOlivier danosLeila adlamLolita petitJuliette hordeauxSylvie berrebiAlain wagnerAravind asokanLouvain drug research instituteInc parisDepartment of pediatrics

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be.

United statesDana cormackAravindhan veerapandiyanOlivier danosChris brinzeyClinical program updatesTechnology platformInternational congressCorporate communicationsManufacturing innovation centerWorld muscle societyExchange commissionTechnology platform licenseesSecurities exchangeBiologics license applicationDuchenne muscular dystrophy

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNEtm Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNEtm Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesOlivier danosAravindhan veerapandiyanChris brinzeyDana cormackWorld muscle societyTechnology platform licenseesCorporate communicationsSecurities exchangeClinical program updatesTechnology platformExchange commissionInternational congressManufacturing innovation centerInterim clinical dataAnnual international congress

Regenxbio (RGNX) Reports Interim Clinical Data from Phase I/II AFFINITY DUCHENNE Trial o RGX-202

Regenxbio (RGNX) Reports Interim Clinical Data from Phase I/II AFFINITY DUCHENNE Trial o RGX-202
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOlivier danosAravindhan veerapandiyanManufacturing innovation centerWorld muscle societyClinical program updatesInternational congressRegenxbio incDuchenne muscular dystrophyAnnual international congressWorld muscleChief scientific officerPediatric neuromuscular neurologistArkansas childrenChief executive officerInnovation center